

ANNEXURE I

Format to be submitted by listed entity on quarterly basis

Name of Listed Entity
 Quarter ending
 Aarti Pharmalabs Limited
 31-Mar-2023

i. Composition Of Board Of Director

Title (Mr./Ms)	Name of the Director	NO	PAN	Category (Chairperson /Executive/Non- Executive/ Independent/ Nominee)	Sub Category	Initial Date of Appointment	Date of Appointment	Date of cessation	Date of Birth	Whether the director is disqualified? Start Date of disqualification End Date of disqualification	Details of disqualification Current status	R Ges R	Date of passing special resolution	No. of Directorship in listed entities including this listed entity [in reference to Regulation 17A (1)]	No of Independent Directorship in listed entities including this listed entity (in reference to proviso to regulation 17A (1)	No of memberships in Audit' Stakeholder Committee(s) including this listed entity	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this	Membership in Committees of the Company	Remarks
Mr.	Rashesh Chandrakant Gogri	00066291	AACPG0778M	C,NED		07-Aug-2021	27-Sep-2021		03-Jun-1974	No	Active	NA		3	0	3	0	RMC,NRC	
Mrs.	Hetal Gogri Gala	00005499	AABPG1598G	ED	MD	07-Aug-2021	17-Oct-2022		10-Jul-1975	No	Active	NA		2	0	2	0	AC,RC	
Mr.	Narendra Jagannath Salvi	00299202	AEAPS3745N	ED	MD	07-Aug-2021	17-Oct-2022		16-Aug-1964	No	Active	NA		3	0	2	0	AC,SC,RC	
Mr.	Rajendra Vallabhaji Gogri	00061003	AACPG2278E	NED		07-Aug-2021	27-Sep-2021		15-Dec-1959	No	Active	NA		3	1	4	1	SC,RC	
Mr.	Parimal Hasmukhlal Desai	00009272	AABPD4102D	NED		17-Oct-2022	10-Jan-2023		29-May-1949	No	Active		10-Jan- 2023	2	0	1	0	RMC	
Mr.	Vinay Gopal Nayak	02577389	AAAPN7530J	ID		17-Oct-2022	17-Oct-2022	5.15	12-Dec-1956	No	Active	NA		2	2	1	0	AC,RC,N RC	
Mr.	Bhavesh Rasiklal Vora	00267604	AAAPV7165K	ID		17-Oct-2022	17-Oct-2022	5.15	13-Sep-1967	No	Active	NA		2	2	3	1	AC,SC	
Mrs.	Jeenal Kenil Savla	07545244	AROPS4872M	ID		17-Oct-2022	17-Oct-2022	5.15	09-Dec-1983	No	Active	NA		1	1	1	0	AC,NRC	
Mrs.	Rupal Vora	07096253	ADJPV9076D	ID		17-Oct-2022	17-Oct-2022	5.15	24-Jun-1963	No	Active	NA		6	6	9	5	SC	
Mr.	Vilas Gajanan Gaikar	00033383	AAAPG7380H	ID		17-Oct-2022	17-Oct-2022	5.15	28-Aug-1960	No	Active	NA		1	1	1	0	AC	

Company Remarks	
Whether Regular	Yes
chairperson appointed	
Whether Chairperson is	Yes
related to MD or CEO	



ii. Composition of Committees

a. Audit Committee

Sr.	Name of Committee	Category	Chairperson/Member	Date of	Date of Cessation
No.	members			Appointment	
1	Bhavesh Rasiklal Vora	ID	Chairperson	17-Oct-2022	
2	Vinay Gopal Nayak	ID	Member	17-Oct-2022	
3	Vilas Gajanan Gaikar	ID	Member	17-Oct-2022	
4	Jeenal Kenil Savla	ID	Member	17-Oct-2022	
5	Hetal Gogri Gala	ED	Member	17-Oct-2022	
6	Narendra Jagannath Salvi	ED	Member	17-Oct-2022	

Company Remarks	
Whether Regular	Yes
chairperson appointed	

b. Stakeholders Relationship Committee

υ. •	b. Stakeholders Relationship Committee					
Sr.	Name of Committee	Category	Chairperson/Member	Date of	Date of Cessation	
No.	members			Appointment		
1	Rajendra Vallabhaji Gogri	NED	Chairperson	17-Oct-2022		
2	Narendra Jagannath Salvi	ED	Member	17-Oct-2022		
3	Bhavesh Rasiklal Vora	ID	Member	17-Oct-2022		
4	Rupal Vora	ID	Member	17-Oct-2022		

Company Remarks	
Whether Regular	Yes
chairperson appointed	

c. Risk Management Committee

Sr.	Name of Committee	Category	Chairperson/Member	Date of	Date of Cessation
No.	members			Appointment	
1	Rashesh Chandrakant	C,NED	Chairperson	17-Oct-2022	
	Gogri		_		
2	Hetal Gogri Gala	ED	Member	17-Oct-2022	
3	Narendra Jagannath Salvi	ED	Member	17-Oct-2022	
4	Rajendra Vallabhaji Gogri	NED	Member	17-Oct-2022	
5	Parimal Hasmukhlal Desai	NED	Member	17-Oct-2022	
6	Vinay Gopal Nayak	ID	Member	17-Oct-2022	

Company Remarks			
Whether Regular	Yes		
chairperson appointed			

d. Nomination and Remuneration Committee

Sr.	Name of Committee	9		Date of	Date of Cessation
No.	members			Appointment	
1	Jeenal Kenil Savla	ID	Chairperson	17-Oct-2022	
2	Vinay Gopal Nayak	ID	Member	17-Oct-2022	
3	Rashesh Chandrakant	C,NED	Member	17-Oct-2022	
	Gogri				



Company Remarks	
Whether Regular	Yes
chairperson appointed	

iii. Meeting of Board of Directors

Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present (All directors including Independent Director)	No. of Independent Directors attending the meeting
17-Oct-2022	Yes	5	5	0
29-Nov-2022	Yes	10	10	5
17-Jan-2023	Yes	10	10	5

Company Remarks	
Maximum gap between any	48
two consecutive (in number of	
days)	

iv. Meeting of Committees

Name of the Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronologica I order)	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committe e as on date of the meeting	Number of Directors present (All directors including Independent Director)	Number of Independen t directors attending the meeting	Number of Members attending the Meeting (Other than Board of Directors)
Stakeholders Relationship Committee	29-Mar-2023	Yes	4	4	2	0
Risk Management Committee	25-Mar-2023	Yes	6	6	1	0
Nomination & Remuneration Committee	17-Jan-2023	Yes	3	3	2	0
Audit Committee	29-Nov-2022	Yes	6	6	4	0
Audit Committee	17-Jan-2023	Yes	6	6	4	0

Company Remarks	
Maximum gap between any	48
two consecutive (in number of	
days) [Only for Audit	
Committee]	



v. Related Party Transactions

Subject	Compliance status (Yes/No/NA)	Remark
Whether prior approval of audit committee obtained	Yes	
Whether shareholder approval obtained for material RPT	Not Applicable	
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes	

VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. **Yes**
- 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
 - a. Audit Committee Yes
 - b. Nomination & remuneration committee Yes
 - c. Stakeholders relationship committee Yes
 - d. Risk management committee (applicable to the top 1000 listed entities) Yes
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. Yes
- 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.Yes
- 5. a. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Yes
 - b. Any comments/observations/advice of Board of Directors may be mentioned here:

Name	•	Nikhil Natu
Name		INIKIIII NALU

Designation : Company Secretary & Compliance Officer



ANNEXURE II

Format to be submitted by listed entity at the end of the financial year (for the whole of financial year)

I. Disclosure on website in terms of Listing Regulat			La	1		
Item		Compliance Compan Websit y (Yes/No/NA) Remark		te		
As per regulation 46(2) of the LODR:						
Details of business				https:/	//www.aartipharmala	bs.com/products-and-service
Terms and conditions of appointment of independent	Yes htt		https:	//www.aartipharmala	bs.com/investors/terms-and-	
Composition of various committees of board of	Yes ht		https:	ttps://www.aartipharmalabs.com/investors/composition		
Code of conduct of board of directors and senior	Yes			https://www.aartipharmalabs.com/investors/code-of-		
Details of establishment of vigil mechanism/ Whistle	Yes			https:	//www.aartipharmala	bs.com/investors/vigil-
Criteria of making payments to non-executive directors	Yes			https:/	//www.aartipharmala	bs.com/investors/nominatio
Policy on dealing with related party transactions	Yes			https:	//www.aartipharmala	bs.com/investors/rpt-policy-
Policy for determining 'material' subsidiaries	Yes			https:	//www.aartipharmala	bs.com/investors/policy-on-
Details of familiarization programs imparted to	Yes			https:/	//www.aartipharmala	bs.com/investors/familiariza
Email address for grievance redressal and other	Yes			https:/	//www.aartipharmala	bs.com/investors-relations
relevant details entity who are responsible for assisting				,	,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Contact information of the designated officials of the	Yes			https:/	//www.aartipharmala	bs.com/investors-relations
Financial results	Yes			https:/	//www.aartipharmala	bs.com/quarterly-results
Shareholding pattern	Yes			https:/	//www.aartipharmala	bs.com/shareholding-patterr
Details of agreements entered into with the media	Not A	Applicable				
companies and/or their associates						
Schedule of analyst or institutional investor meet and	Not Applicable					
presentations madeby the listed entity to analysts or						
New name and the old name of the listed entity	Yes	https://www.aartipharmalabs.com/		bs.com/		
Advertisements as per regulation 47 (1)	Yes			https://www.aartipharmalabs.com/newspaper-		bs.com/newspaper-
Credit rating or revision in credit rating obtained by the	Yes			https://www.aartipharmalabs.com/credit-ratings		bs.com/credit-ratings
Separate audited financial statements of each	Yes			https:,	tps://www.aartipharmalabs.com/subsidiary-co	
As per other regulations of the LODR:						
Whether company has provided information under		https://www.aartipharmalabs.com/disc		bs.com/disclosures-under-		
separate section on its website as per Regulation 46(2)	Yes reg		regula	regulation-46-of-the-sebi-lodr-regulations-2015		
Materiality Policy as per Regulation 30	Yes			https:/	https://www.aartipharmalabs.com/investors/policy	
Dividend Distribution policy as per Regulation 43A (as	Yes			https:/	//www.aartipharmala	bs.com/investors/dividend-
It is certified that these contents on the website of the	Yes			https:/	nttps://www.aartipharmalabs.com/	
II Annual Affirmations				1		
Particulars		Regulation Number		Compliance status (Yes/No/NA)	Company Remark	
Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'		16(1)(b) & 25(6)		Yes		
Board composition		17(1), 17(1A) & 17(1B)		Yes		
Meeting of Board of directors		17(2)		Yes		
Quorum of Board meeting		17(2A)		Yes		
Review of Compliance Reports		17(3)		Yes		



Plans for orderly succession for appointments	17(4)	Yes
Code of Conduct	17(5)	Yes
Fees/compensation	17(6)	Yes
Minimum Information	17(7)	Yes
Compliance Certificate	17(8)	Yes
Risk Assessment & Management	17(9)	Yes
Performance Evaluation of Independent Directors	17(10)	Yes
Recommendation of Board	17(11)	Yes
Maximum number of directorship	17A	Yes
Composition of Audit Committee	18(1)	Yes
Meeting of Audit Committee	18(2)	Yes
Composition of nomination & remuneration committee	19(1) & (2)	Yes
Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes
Meeting of nomination & remuneration committee	19(3A)	Yes
Composition of Stakeholder Relationship Committee	20(1), 20(2) and 20(2A)	Yes
Meeting of stakeholder relationship committee	20(3A)	Yes
Composition and role of risk management committee	21(1),(2),(3),(4)	Yes
Meeting of Risk Management Committee	21(3A)	Yes
Vigil Mechanism	22	Yes
Policy for related party Transaction	23(1),(1A),(5),(6),(7)	Yes
Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes
Approval for material related party transactions	23(4)	Not Applicable
Disclosure of related party transactions on consolidated basis	23(9)	Yes
Composition of Board of Directors of unlisted material Subsidiary	24(1)	Not Applicable
Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes
Annual Secretarial Compliance Report	24(A)	Yes
Alternate Director to Independent Director	25(1)	Not Applicable
Maximum Tenure	25(2)	Yes
Meeting of independent directors	25(3) & (4)	Yes
Familiarization of independent directors	25(7)	Yes
Declaration from Independent Director	25(8) & (9)	Yes
D & O Insurance for Independent Directors	25(10)	Yes
Memberships in Committees	26(1)	Yes



Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
Disclosure of Shareholding by Non- Executive Directors	26(4)	Not Applicable	
Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	

Other Information	

III Affirmations:

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied. **- Yes**

Other Information	

Name : Nikhil Natu

Designation : Company Secretary & Compliance Officer



ANNEXURE IV

%symbol%	%companyName%	%quarterEnded%

(A) Any loan or any other form of debt advanced by the listed entity directly or indirectly to

Aggregate amount advanced during six months			Balance outstanding at the end of six months				
Promoter or any other entity controlled by them	Promoter Group or any other entity controlled by them	Directors (including relatives) or any other entity controlled by them	KMPs or any other entity controlled by them	Promot er or any other entity controll ed by them	Promoter Group or any other entity controlled by them	Directors (including relatives) or any other entity controlled by them	KMPs or any other entity controlled by them
0	0	0	0	0	0	0	0

(B) Any guarantee/ comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months (taking into account any invocation)
Promoter or any other entity controlled by them	NA	0	0
Promoter Group or any other entity controlled by them	NA	0	0
Directors (including relatives) or any other entity controlled by them	NA	0	0
KMPs or any other entity controlled by them	NA	0	0



(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type of Security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	NA	0	0
Promoter Group or any other entity controlled by them	NA	0	0
Directors (including relatives) or any other entity controlled by them	NA	0	0
KMPs or any other entity controlled by them	NA	0	0

(D) If the Listed Entity would like to provide any other information the same may be indicated here				

Affirmations

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company

Company Remarks in	
case of non-	
compliant status	

Name: Piyush Lakhani

Designation: Chief Financial

Officer

Place: Mumbai Date: 17-Apr-2023